A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer

Brief description of study

You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you have elected to receive chemotherapy and surgery to treat your disease. This study utilizes a novel GEN-1 (IL-12 Plasmid) with neoadjuvant chemotherapy in newly diagnosed patients with advanced ovarian, fallopian tube or primary peritoneal cancer.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.